Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cost-effectiveness of Aryoseven vs FEIBA in hemophilia
IRCT2013020612380N1Phase 3Completed
- Sponsor
- AryoGen Biopharma
- Start
- Feb 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of AryoSeven and anti-inhibitor coagulant complex in hemophilia (2 arms), sponsored by AryoGen Biopharma. Primary endpoint: Cost-effectiveness comparison of Aryoseven versus FEIBA. Started Feb 2013; status: completed.
02
Drugs
AryoSevenanti-inhibitor coagulant complex
03
Conditions
hemophilia
Beyond the preview
Go deeper on IRCT2013020612380N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2013020612380N1.